This site uses cookies to store information on your computer. Learn more x

Pharma joint ventures

Leveraging partnerships for growth

DSM’s former Pharma Cluster now consists of DPx Holdings, formed by combining DSM Pharmaceutical Products and Patheon Inc., a leading provider of CDMO services, pharmaceutical products and other formulated products for various industries, and DSM's joint venture interest in DSM Sinochem Pharmaceuticals, leader in beta-lactam anti-infectives.

Leveraging partnerships for growth

In 2014, DSM completed the fourth year of its successful strategy 'DSM in motion: driving focused growth', which it launched in 2010 to become a global leader in health, nutrition and materials. The strategy’s objective for our Pharma Cluster was Leveraging partnerships for growth.

DSM Sinochem Pharmaceuticals

DSM Sinochem Pharmaceuticals

In August 2011 DSM announced that it had established the 50/50 global joint venture for its business group DSM Anti-Infectives with the Sinochem Group, DSM Sinochem Pharmaceuticals.

DPx Holdings

DPx Holdings B.V.

In March 2014 DSM and JLL Partners (JLL), the middle-market private equity firm, announced that DPx Holdings B.V. was operational.

DPx Holdings is the privately held parent company of the Patheon®, DPx Fine Chemicals™ and Banner Life Sciences™ businesses, and is a leading provider of CDMO services, pharmaceutical products and select chemical products for other industries.

Cluster strategy concluded

With the announcement on 11 March 2014 that DPx Holdings was operational, DSM concluded its strategic objectives of Leveraging partnerships for growth for its Pharma cluster.

Equity method

Accordingly, as of 1 January 2014 the Pharma cluster is no longer included in DSM’s core EBITDA or activities and DSM reports on its investments in joint ventures as an associated account in accordance with the equity method rather than as ongoing business.